MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- International - indian pharma
- DISHMAN PHARMA - ACTAVIS (US)
DISHMAN PHARMA vs ACTAVIS (US) - Comparison Results
DISHMAN PHARMA Change
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
ACTAVIS (US)
Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More
Financials
 DISHMAN PHARMA  ACTAVIS |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| DISHMAN PHARMA Mar-16 |
ACTAVIS Dec-18 |
DISHMAN PHARMA/ ACTAVIS |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 374 | 14,207 | - | |
| Low | Rs | 129 | 9,530 | - | |
| Sales per share (Unadj.) | Rs | 197.8 | 3,484.9 | - | |
| Earnings per share (Unadj.) | Rs | 21.2 | -1,122.5 | - | |
| Cash flow per share (Unadj.) | Rs | 34.7 | 367.2 | - | |
| Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
| Dividend yield (eoy) | % | 0.8 | 0 | - | |
| Book value per share (Unadj.) | Rs | 179.9 | 14,373.6 | - | |
| Shares outstanding (eoy) | m | 80.69 | 332.60 | - | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 1.3 | 3.4 | 37.4% | |
| Avg P/E ratio | x | 11.9 | -10.6 | -112.2% | |
| P/CF ratio (eoy) | x | 7.2 | 32.3 | 22.4% | |
| Price / Book Value ratio | x | 1.4 | 0.8 | 169.4% | |
| Dividend payout | % | 9.4 | 0 | - | |
| Avg Mkt Cap | Rs m | 20,306 | 3,947,411 | 0.5% | |
| No. of employees | `000 | 0.8 | 16.9 | 4.9% | |
| Total wages/salary | Rs m | 5,355 | 0 | - | |
| Avg. sales/employee | Rs Th | 19,252.7 | 68,584.7 | 28.1% | |
| Avg. wages/employee | Rs Th | 6,459.5 | 0 | - | |
| Avg. net profit/employee | Rs Th | 2,064.1 | -22,091.2 | -9.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 15,961 | 1,159,082 | 1.4% | |
| Other income | Rs m | 265 | 22,165 | 1.2% | |
| Total revenues | Rs m | 16,226 | 1,181,247 | 1.4% | |
| Gross profit | Rs m | 4,103 | 30,374 | 13.5% | |
| Depreciation | Rs m | 1,091 | 495,482 | 0.2% | |
| Interest | Rs m | 944 | 66,886 | 1.4% | |
| Profit before tax | Rs m | 2,334 | -509,828 | -0.5% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 1 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 130,027 | 0.0% | |
| Tax | Rs m | 624 | -6,461 | -9.7% | |
| Profit after tax | Rs m | 1,711 | -373,341 | -0.5% | |
| Gross profit margin | % | 25.7 | 2.6 | 981.0% | |
| Effective tax rate | % | 26.7 | 1.3 | 2,108.7% | |
| Net profit margin | % | 10.7 | -32.2 | -33.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 11,018 | 475,395 | 2.3% | |
| Current liabilities | Rs m | 9,517 | 420,550 | 2.3% | |
| Net working cap to sales | % | 9.4 | 4.7 | 198.7% | |
| Current ratio | x | 1.2 | 1.1 | 102.4% | |
| Inventory Days | Days | 110 | 20 | 564.2% | |
| Debtors Days | Days | 35 | 66 | 52.5% | |
| Net fixed assets | Rs m | 16,304 | 131,202 | 12.4% | |
| Share capital | Rs m | 161 | 0 | - | |
| Net worth | Rs m | 14,516 | 4,780,670 | 0.3% | |
| Long term debt | Rs m | 4,189 | 1,683,447 | 0.2% | |
| Total assets | Rs m | 29,805 | 7,473,275 | 0.4% | |
| Interest coverage | x | 3.5 | -6.6 | -52.4% | |
| Debt to equity ratio | x | 0.3 | 0.4 | 82.0% | |
| Sales to assets ratio | x | 0.5 | 0.2 | 345.3% | |
| Return on assets | % | 8.9 | -4.1 | -217.3% | |
| Return on equity | % | 11.8 | -7.8 | -150.9% | |
| Return on capital | % | 17.5 | -4.8 | -362.1% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 2,786 | 414,096 | 0.7% | |
| From Investments | Rs m | -1,529 | 227,492 | -0.7% | |
| From Financial Activity | Rs m | -941 | -710,713 | 0.1% | |
| Net Cashflow | Rs m | 316 | -68,780 | -0.5% | |
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.42 Rs / USD
Compare DISHMAN PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
Compare DISHMAN PHARMA With: DIVIS LABORATORIES ALKEM LABORATORIES TTK HEALTHCARE CADILA HEALTHCARE GSK PHARMA
Today's Market
Sensex Ends 447 Points Higher; Automobile & IT Stocks Rally(Closing)
Indian share markets witnessed buying interest during closing hours and ended today's volatile session higher.
Related Views On News
Most Popular
It's the Beginning of a New Bull Phase in Smallcaps (Profit Hunter)
Feb 24, 2021Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
Make Rs 5,000 Per Day Trading the Market (Fast Profits Daily)
Feb 25, 2021In this video, I'll show you how to get started on the path to daily trading profits.
I Believe the Investment of the Year Will Be...
Feb 19, 2021In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
The Hidden Tesla in My Great Indian Wealth Project (Profit Hunter)
Feb 23, 2021An Indian company founded three decades ago in a garage caught my attention...
More
